The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
The tumour micro-environment (TME) plays a crucial role in the onset and progression of prostate cancer (PCa). Here we studied the potential of a selected panel of TME-markers to predict clinical recurrence (CLR) in PCa. Patient cohorts were matched for the presence or absence of CLR 5 years post-pr...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0244663 |
id |
doaj-ec82bfb8bd3541ba89838661fe6c91c8 |
---|---|
record_format |
Article |
spelling |
doaj-ec82bfb8bd3541ba89838661fe6c91c82021-03-23T05:31:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-011512e024466310.1371/journal.pone.0244663The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.Thomas GevaertYves-Rémi Van EyckeThomas Vanden BroeckHein Van PoppelIsabelle SalmonSandrine RoriveTim MuilwijkFrank ClaessensDirk De RidderSteven JoniauChristine DecaesteckerThe tumour micro-environment (TME) plays a crucial role in the onset and progression of prostate cancer (PCa). Here we studied the potential of a selected panel of TME-markers to predict clinical recurrence (CLR) in PCa. Patient cohorts were matched for the presence or absence of CLR 5 years post-prostatectomy. Tissue micro-arrays (TMA) were composed with both prostate non-tumour (PNT) and PCa tissue and subsequently processed for immunohistochemistry (IHC). The IHC panel included markers for cancer activated fibroblasts (CAFs), blood vessels and steroid hormone receptors ((SHR): androgen receptor (AR), progesterone receptor (PR) and estrogen receptor (ER)). Stained slides were digitalised, selectively annotated and analysed for percentage of marker expression with standardized and validated image analysis algorithms. A univariable analysis identified several TME markers with significant impact on CR: expression of CD31 (vascular marker) in PNT stroma, expression of alpha smooth muscle actin (αSMA) in PCa stroma, and PR expression ratio between PCa stroma and PNT stroma. A multivariable model, which included CD31 expression (vascular marker) in PNT stroma and PR expression ratio between PCa stroma and PNT stroma, could significantly stratify patients for CLR, with the identification of a low risk and high-risk subgroup. If validated and confirmed in an independent prospective series, this subgroup might have clinical potential for PCa patient stratification.https://doi.org/10.1371/journal.pone.0244663 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Thomas Gevaert Yves-Rémi Van Eycke Thomas Vanden Broeck Hein Van Poppel Isabelle Salmon Sandrine Rorive Tim Muilwijk Frank Claessens Dirk De Ridder Steven Joniau Christine Decaestecker |
spellingShingle |
Thomas Gevaert Yves-Rémi Van Eycke Thomas Vanden Broeck Hein Van Poppel Isabelle Salmon Sandrine Rorive Tim Muilwijk Frank Claessens Dirk De Ridder Steven Joniau Christine Decaestecker The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. PLoS ONE |
author_facet |
Thomas Gevaert Yves-Rémi Van Eycke Thomas Vanden Broeck Hein Van Poppel Isabelle Salmon Sandrine Rorive Tim Muilwijk Frank Claessens Dirk De Ridder Steven Joniau Christine Decaestecker |
author_sort |
Thomas Gevaert |
title |
The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. |
title_short |
The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. |
title_full |
The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. |
title_fullStr |
The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. |
title_full_unstemmed |
The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. |
title_sort |
potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2020-01-01 |
description |
The tumour micro-environment (TME) plays a crucial role in the onset and progression of prostate cancer (PCa). Here we studied the potential of a selected panel of TME-markers to predict clinical recurrence (CLR) in PCa. Patient cohorts were matched for the presence or absence of CLR 5 years post-prostatectomy. Tissue micro-arrays (TMA) were composed with both prostate non-tumour (PNT) and PCa tissue and subsequently processed for immunohistochemistry (IHC). The IHC panel included markers for cancer activated fibroblasts (CAFs), blood vessels and steroid hormone receptors ((SHR): androgen receptor (AR), progesterone receptor (PR) and estrogen receptor (ER)). Stained slides were digitalised, selectively annotated and analysed for percentage of marker expression with standardized and validated image analysis algorithms. A univariable analysis identified several TME markers with significant impact on CR: expression of CD31 (vascular marker) in PNT stroma, expression of alpha smooth muscle actin (αSMA) in PCa stroma, and PR expression ratio between PCa stroma and PNT stroma. A multivariable model, which included CD31 expression (vascular marker) in PNT stroma and PR expression ratio between PCa stroma and PNT stroma, could significantly stratify patients for CLR, with the identification of a low risk and high-risk subgroup. If validated and confirmed in an independent prospective series, this subgroup might have clinical potential for PCa patient stratification. |
url |
https://doi.org/10.1371/journal.pone.0244663 |
work_keys_str_mv |
AT thomasgevaert thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT yvesremivaneycke thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT thomasvandenbroeck thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT heinvanpoppel thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT isabellesalmon thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT sandrinerorive thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT timmuilwijk thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT frankclaessens thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT dirkderidder thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT stevenjoniau thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT christinedecaestecker thepotentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT thomasgevaert potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT yvesremivaneycke potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT thomasvandenbroeck potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT heinvanpoppel potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT isabellesalmon potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT sandrinerorive potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT timmuilwijk potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT frankclaessens potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT dirkderidder potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT stevenjoniau potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients AT christinedecaestecker potentialoftumourmicroenvironmentmarkerstostratifytheriskofrecurrenceinprostatecancerpatients |
_version_ |
1714769348081483776 |